Huperzine A Powder (Huperzine A) is a natural alkaloid extracted from the Taxaceae plant Melastomataceae, belonging to the class of potent, highly selective, and reversible acetylcholinesterase (AChE) inhibitors. It has been used to treat inflammation, fever, and cognitive impairment. Modern research has confirmed that it has significant neuroprotective effects and has become an important drug for treating neurodegenerative diseases such as Alzheimer's disease. The appearance is a slightly yellow to white crystalline powder, easily soluble in chloroform, methanol, ethanol, and slightly soluble in water. It is rapidly and completely absorbed orally, with a bioavailability of up to 96.6%. It easily penetrates the blood-brain barrier and is widely distributed in the brain, mainly in the frontal lobe, temporal lobe, hippocampus, and other brain areas closely related to learning and memory. It inhibits the activity of acetylcholinesterase, prevents the breakdown of acetylcholine (ACh), thereby increasing the concentration of ACh in synaptic cleft and enhancing cholinergic neurotransmission. In addition, it may also provide neuroprotection by regulating NMDA receptors and antioxidant activity. It can improve the cognitive function, memory, and daily living ability of patients with mild to moderate Alzheimer's disease. Some studies have shown that its efficacy is superior to traditional drugs such as donepezil, and it may also play a role by improving cerebral blood flow and neuroplasticity.
 |
 |
Huperzine A COA
Huperzine A Powder is a natural alkaloid extracted from the Cryptomeriaceae plant, Taxodium erinaceus, which exhibits potent, highly selective, and reversible acetylcholinesterase (AChE) inhibition. In recent years, its application in neurodegenerative diseases, cognitive impairment, myasthenia gravis and other fields has received widespread attention. The following is a detailed explanation of its purpose:
Application of Huperzine A in Neurodegenerative Diseases
Alzheimer's disease
Huperzine A inhibits the activity of AChE, prevents the breakdown of acetylcholine (ACh), thereby increasing the concentration of ACh in synaptic cleft and enhancing cholinergic neurotransmission. In addition, huperzine A can provide neuroprotection by regulating NMDA receptors and antioxidant activity. Multiple clinical trials have shown that huperzine A can significantly improve cognitive function, memory, and daily living abilities in patients with mild to moderate Alzheimer's disease. For example, a 12 week randomized controlled trial showed that patients in the huperzine A group had significantly higher MMSE (Mini Mental State Examination) scores than those in the placebo group. Compared with traditional AChE inhibitors such as donepezil, huperzine A has higher selectivity, fewer side effects, and longer duration of action.
Vascular dementia&Parkinson's disease
Huperzine A may alleviate cognitive impairment in patients with vascular dementia by improving cerebral blood flow and neuroplasticity. A study on patients with vascular dementia showed that huperzine A can significantly improve their cognitive function and daily living ability. Although research on huperzine A in Parkinson's disease is relatively limited, some preliminary studies suggest that it may improve motor symptoms and cognitive function in Parkinson's disease patients by regulating the balance between the dopaminergic and cholinergic systems.
Application in myasthenia gravis
Huperzine A enhances the transmission of neuromuscular junctions and improves muscle weakness symptoms by inhibiting the activity of AChE and increasing the concentration of ACh in synaptic cleft. A study on patients with myasthenia gravis showed that Huperzine A has an effective rate of 99% and can significantly improve muscle strength and motor function in patients. Another study showed that Huperzine A has a longer duration of action and fewer side effects compared to traditional acetylcholinesterase drugs such as neostigmine. The advantage of Huperzine A in the treatment of myasthenia gravis lies in its potent and reversible AChE inhibitory effect, with fewer side effects on the central nervous system.
Application in cognitive impairment
Huperzine A improves memory and learning function by enhancing cholinergic neurotransmission. Multiple studies have shown that Huperzine A can improve the directional memory, associative learning, image recall, meaningless graphic recognition, and portrait recall abilities of patients with benign memory impairment. Suitable for middle-aged and elderly people with memory impairment caused by aging or mild brain injury. Huperzine A may improve cognitive function in patients with schizophrenia by regulating the balance of the dopaminergic and cholinergic systems. Some studies have shown that Huperzine A has a significant improvement effect on association disorders, cognitive impairment, and memory loss associated with schizophrenia. Huperzine A can be used to treat memory impairment caused by cerebrovascular disorders, traumatic brain injury, encephalitis, etc.
Applications in other fields
Neuroprotective&Antidepressant Effects&Improving Sleep Quality
Huperzine A can protect neurons from damage through its antioxidant, anti-inflammatory, and anti apoptotic effects. Animal experiments have shown that Huperzine A can alleviate neuronal damage caused by cerebral ischemia, traumatic brain injury, and neurodegenerative diseases. Some preliminary studies suggest that Huperzine A may improve depressive symptoms by regulating the levels of monoamine neurotransmitters such as serotonin and dopamine. Huperzine A may indirectly improve sleep quality by regulating the cholinergic system and improving cognitive function. Some patients have reported an improvement in sleep quality after using Huperzine A.
Fluorescent labeling experiment of Huperzine A in enhancing dynamic connectivity of neuronal mitochondrial networks
Mitochondria, as the "energy factory" of cells, not only play a core role in energy metabolism in neurons, but also participate in key physiological processes such as cell signaling, calcium homeostasis regulation, and apoptosis regulation. Research has shown that neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease are often accompanied by mitochondrial dysfunction and abnormal dynamic connectivity, leading to energy metabolism disorders, increased oxidative stress, and neuronal apoptosis. Huperzine A Powder is a natural alkaloid extracted from plants in the family Taxaceae, which exhibits potent and highly selective acetylcholinesterase (AChE) inhibition. The use of fluorescence labeling technology to study the effect of Huperzine A on the dynamic connectivity of neuronal mitochondrial networks is of great significance for revealing its neuroprotective mechanism：
The neuroprotective effect and mitochondrial function of Huperzine A
The neuroprotective effect of Huperzine A
Huperzine A enhances cholinergic neurotransmission and improves cognitive function by inhibiting AChE activity and increasing the concentration of acetylcholine (ACh) in synaptic cleft. In addition, Huperzine A also has antioxidant, anti-inflammatory, and anti apoptotic effects, which can alleviate neuronal damage.
Mitochondrial function and neurodegenerative diseases
Mitochondrial dysfunction is one of the important pathological features of neurodegenerative diseases. Abnormal mitochondrial dynamic connectivity (such as fusion and fission imbalance) can lead to abnormal mitochondrial morphology, energy metabolism disorders, and increased oxidative stress, thereby triggering neuronal apoptosis.
The relationship between Huperzine A and mitochondrial function
Research has shown that Huperzine A can alleviate neuronal mitochondrial damage induced by β - amyloid (A β), hydrogen peroxide, etc., protect mitochondrial membrane potential, and reduce cell apoptosis. In addition, Huperzine A may also affect mitochondrial dynamic connectivity by regulating the expression of mitochondrial fusion and fission related proteins (such as Mfn1, Mfn2, Drp1).
Application of Fluorescence Labeling Technology in the Study of Neuronal Mitochondria
Principles of Fluorescent Labeling Technology
Fluorescence labeling technology combines fluorescent proteins or dyes with target molecules (such as mitochondria) and observes the dynamic behavior of the target molecules using a fluorescence microscope. Common mitochondrial fluorescent markers include:
Fluorescent proteins such as mito GFP and mito RFP are expressed in mitochondria through gene transfection techniques.
Fluorescent dyes, such as MitoTracker, can specifically bind to mitochondrial membrane potential and are suitable for live cell imaging.
Application of Fluorescence Labeling Technology in the Study of Neuronal Mitochondria
Observation of mitochondrial morphology and distribution: Through fluorescent labeling, the morphology (such as tubular or granular) and distribution characteristics of mitochondria in neurons can be visually observed.
Mitochondrial trajectory tracking: Combined with time series imaging technology, it can record the transport trajectory and velocity of mitochondria in neuronal axons and dendrites.
Mitochondrial fusion and fission event detection: Through high-resolution imaging technology, the dynamic process of mitochondrial fusion and fission can be observed, and the fusion and fission frequency can be quantitatively analyzed.
Experimental design on the influence of dynamic connections in neuronal mitochondrial networks
Experimental Materials and Methods
experimental materials:
Cell model: Primary cultured rat hippocampal neurons or human neuroblastoma cell lines (such as SH-SY5Y).
Fluorescent markers: mito GFP (gene transfection) or MitoTracker Red (fluorescent dye).
Drug: Huperzine A (with different concentration gradients).
Instruments: confocal microscope, super-resolution microscope, cell culture incubator, etc.
Experimental method:
Neurons are seeded in confocal culture dishes and cultured for a specific period of time before transfection with mito GFP plasmid or addition of MitoTracker Red dye.
Neurons were divided into a control group and a Huperzine A treatment group (at different concentrations), and imaging was performed after a specific treatment time.
Using confocal microscopy or super-resolution microscopy to perform time-series imaging of neurons and record the dynamic behavior of mitochondria.
Mitochondrial morphology analysis: Calculate the length, number of branches, and morphology index of mitochondria.
Mitochondrial motion trajectory analysis: Track the motion trajectory of mitochondria, calculate average velocity and displacement.
Analysis of mitochondrial fusion and fission events: Count the frequency of fusion and fission events and calculate the fusion and fission index.
Expected experimental results
Mitochondrial morphology and distribution
After treatment with Huperzine A, the morphology of neuronal mitochondria may become more regular and evenly distributed.
Mitochondrial motility
Huperzine A may enhance the transport capacity of mitochondria in neuronal axons and dendrites, and improve the dynamic connectivity of mitochondria.
Mitochondrial fusion and division
Huperzine A Powder may regulate the expression of mitochondrial fusion and division related proteins, promote mitochondrial fusion, and inhibit excessive division.
Hot Tags: huperzine a powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, API Researching Only , epinephrine powder, larocaine hydrochloride, levamisole hydrochloride powder, Medetomidine hydrochloride, tetramisole hcl powder